Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study.

ABSTRACT:

Background

China has a large number of myasthenia gravis (MG) patients, creating an urgent need for rapid and tolerable treatment options. As the first-approved Fc receptor antagonist, efgartigimod has bright prospects for treating MG. However, real-world evidence on its application within the Chinese MG population are limited.

Objective

This study aims to evaluate the rapid efficacy and safety of efgartigimod in Chinese MG population.

Design

This single-center prospective study enrolled Chinese MG patients aged 18 and older who were treated with efgartigimod, classified as Myasthenia Gravis Foundation of America I-IV, with a baseline Myasthenia Gravis Activities of Daily Living (MG-ADL) score of at least 4.

Methods

Patients received efgartigimod at a dose of 1

SUBMITTER: Zhu G 

PROVIDER: S-EPMC11748066 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature